Access cutting-edge lung cancer treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in Minneapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central r
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this lung cancer clinical trial in Minneapolis, MN
If you're searching for lung cancer treatment options in Minneapolis, MN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.